On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
HOME > ORGANIZATION
ORGANIZATION
- Interview with Alfonso G. Zulueta of PhRMA
May 14, 2012
- Greater Concern than Hope about HTA: Mr Zulueta of PhRMA
May 14, 2012
- Participation in TPP to Lead to Higher NHI Prices: JMA VP Nakagawa
May 10, 2012
- 87% of Respondents Affirmative on Introduction of Medicoeconomic Assessment: JAPhMed Survey
May 9, 2012
- JPMA Compiles Manual for Providing Drugs in the Event of Disasters
April 24, 2012
- JPMA Opposes Haste Adoption of Cost-Effective HTA
April 20, 2012
- National Centers for Advanced and Specialized Medical Cares to Join NHO, JLHWO Hospitals in Joint Purchasing
April 20, 2012
- Degree of Drug Contribution Increased Most for HIV and AIDS: JHSF Survey
April 13, 2012
- MREAC Seeks to Contact 70 People Who Passed MR Exam through “Transitional Measure”
April 10, 2012
- CMRs Exceed 3000, Rapidly Increasing in Specialty Care: JCSOA
April 6, 2012
- 4 Specific Measures for Distribution Improvement: JPWA President Bessho
March 29, 2012
- JGA Announces GL for Disclosure of Payments to Medical Institutions by Member Companies
March 29, 2012
- JGA Announces Measures to Ensure Stable Supplies of Generic Drugs
March 27, 2012
- JGA to Start Providing Information in July on Out of Stock Generics
March 27, 2012
- NIBIO Offers Clinical Trial Information on Rare Diseases on Website
March 26, 2012
- Growth of Domestic Pharma Industry Will Require Individualized Strategies: FPMAJ Chairman Shoda
March 23, 2012
- IDMA President Doshi Expresses Hopes for Cooperation with Japanese Pharmaceutical Companies
March 21, 2012
- Drugstore Market Reaches ¥5.8 Trillion, 11 Straight Years of Growth: JACDS Survey
March 19, 2012
- Asia Partnership Conference Starts Talks for Early NDA Approval at Inauguration Meeting in Tokyo
March 19, 2012
- JMA “Totally Opposed” to Japan’s Participation in TPP
March 16, 2012
ページ
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…